[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]

# ![@Drlipid Avatar](https://lunarcrush.com/gi/w:26/cr:twitter::56916619.png) @Drlipid Thomas Dayspring

Thomas Dayspring posts on X about  the most. They currently have XXXXXX followers and XXX posts still getting attention that total XX engagements in the last XX hours.

### Engagements: XX [#](/creator/twitter::56916619/interactions)
![Engagements Line Chart](https://lunarcrush.com/gi/w:600/cr:twitter::56916619/c:line/m:interactions.svg)

- X Week XXX -XX%
- X Month XXXXXX +668%
- X Months XXXXXXX +43%
- X Year XXXXXXX -XX%

### Mentions: X [#](/creator/twitter::56916619/posts_active)
![Mentions Line Chart](https://lunarcrush.com/gi/w:600/cr:twitter::56916619/c:line/m:posts_active.svg)

- X Week X -XX%
- X Month XX +143%
- X Months XX +63%
- X Year XXX -XX%

### Followers: XXXXXX [#](/creator/twitter::56916619/followers)
![Followers Line Chart](https://lunarcrush.com/gi/w:600/cr:twitter::56916619/c:line/m:followers.svg)

- X Week XXXXXX +2.60%
- X Month XXXXXX +4.60%
- X Months XXXXXX +7.90%
- X Year XXXXXX +13%

### CreatorRank: undefined [#](/creator/twitter::56916619/influencer_rank)
![CreatorRank Line Chart](https://lunarcrush.com/gi/w:600/cr:twitter::56916619/c:line/m:influencer_rank.svg)

### Social Influence

**Social category influence**
[stocks](/list/stocks) 

**Top accounts mentioned or mentioned by**
[@nationallipid](/creator/undefined) [@societyeas](/creator/undefined) [@escardio](/creator/undefined) [@atherosociety](/creator/undefined) [@fhpatienteurope](/creator/undefined) [@familyheartfdn](/creator/undefined) [@aspcardio](/creator/undefined) [@thefhfoundation](/creator/undefined) [@johnkastelein](/creator/undefined) [@mohammedalo](/creator/undefined) [@menopauseorg](/creator/undefined) [@peterattiamd](/creator/undefined) [@drpablocorral](/creator/undefined) [@theproof](/creator/undefined) [@societyea](/creator/undefined) [@lipofan](/creator/undefined) [@amgen](/creator/undefined) [@nutritionmades3](/creator/undefined) [@marketpicker](/creator/undefined) [@cardiobrief](/creator/undefined)
### Top Social Posts
Top posts by engagements in the last XX hours

"Amgen is to be congratulated with another successful evolocumab (Repatha) trial: VESALIUS-CV should be a kick in the butt to the majority of real-world clinicians including University clinics whose data demonstrates they are nowhere close to appropriately (meaning aggressively) treating high-risk lipid disorders. In these high-risk folks the BASELINE LDL-C was XXX mg/dL which is pathetic undertreatment. How is this possible in 2025 Adding Repatha improved LDL metrics and further reduced 3- or 4-point MACE. Results should teach all that combo Rx is the new standard. @nationallipid @society_eas"  
[X Link](https://x.com/Drlipid/status/1987614017737621958)  2025-11-09T20:11Z 44.1K followers, 15.2K engagements


"The PCSK9 inhibitor that has by far the most clinical trial evidence with efficacy & safety is evolocumab (Repatha) in 60000 patients. Of interest is how @Amgen named most of the trials: take a historical trip thru the world's great scientists. If I missed any trials let me know @nationallipid @society_eas @ASPCardio @escardio @atherosociety @FamilyHeartFdn"  
[X Link](https://x.com/Drlipid/status/1988044150684385410)  2025-11-11T00:40Z 44.1K followers, 10.4K engagements